The BAG5 Knockout HT29 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout population derived from the HT29 colorectal adenocarcinoma cell line, featuring targeted disruption of the BAG5 gene encoding the Bcl-2-associated athanogene 5 co-chaperone. This polyclonal format yields a heterogeneous loss-of-function model that avoids clonal artifacts and is well-suited for studying BAG5 functions in a genetically diverse cell pool.
HT29 is a widely utilized human colorectal adenocarcinoma line characterized by a homozygous p53 mutation (R273H), epithelial morphology, and tumorigenic capacity in xenograft models. Its oncogenic background and reliable growth properties establish a robust platform for dissecting signaling pathways and therapeutic vulnerabilities in colorectal cancer research.
BAG5 acts as a negative regulator of Hsp70 chaperone activity by binding HSPA1A and HSPA8 via its BAG domain, inhibiting substrate refolding and promoting ubiquitin-dependent degradation through interaction with CHIP (STUB1). It also modulates Parkin (PRKN) E3 ligase function and alpha-synuclein (SNCA) aggregation, linking proteostasis to apoptosis via BCL2 and caspase-3 (CASP3). Cellular stress stimuli regulate BAG5 expression, positioning it at the interface of protein quality control and cell death signaling.
In the HT29 context, BAG5 knockout disrupts a key proteostasis node, potentially altering tumor cell survival under proteotoxic conditions and modifying drug sensitivity. This model enables dissection of cross-talk between mutant p53 and chaperone networks, and it offers a non-neuronal system to investigate Parkinson??s disease-associated protein aggregation via BAG5??s modulation of alpha-synuclein and parkin. Consequently, these cells support studies on the intersection of cancer biology and neurodegeneration.
Researchers may utilize Western blotting, co-immunoprecipitation, and immunofluorescence microscopy to probe BAG5?CHsp70 complexes and downstream signaling events. Functional assays including Annexin V/propidium iodide apoptosis detection, flow cytometry, and MTT cell viability measurements permit quantitative assessment of death pathways and drug responses. Ubiquitin-proteasome activity assays and drug sensitivity screening further evaluate proteostasis alterations. For additional information or technical support regarding the BAG5 Knockout HT29 Polyclonal Cells, please contact Ascent Research.
